IL21 and neoplasm: Using a subcutaneous mouse model of colon cancer, we confirmed a combination of recombinant free IL-21 and anti-PD-1 antibody (mAb) dosed concurrently, extended survival, in an established tumor model (Supplementary Figure S1A).